Naslov
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Autori
Michallet, Mauricette ; Dreger, Peter ; Sobh, Mohamad ; Koster, Linda ; Hoek, Jennifer ; Boumendil, Ariane ; Scheid, Christof ; Fox, Christopher P ; Wulf, Gerald ; Krüger, William ; van Gelder, Michel ; Corradini, Paolo ; Russo, Domenico ; Passweg, Jakob ; Schoemans, Hélène ; Bethge, Wolfgang ; Schaap, Nicolaas ; Cornelissen, Jan ; Browne, Paul ; Duraković, Nadira ; Lutz, Muller ; Montoto, Silvia ; Kroger, Nicolaus ; Schetelig ; Johannes

Kolaboracija
French Cooperative Group for CLL ; SFGM-TC ; EBMT Chronic Malignancy and Lymphoma Working Parties

Izvornik
Bone marrow transplantation (Basingstoke) (0268-3369) 55 (2020), 5; 884-890

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ibrutinib ; salvage ; bone marrow transplantation

Sažetak
The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males ; median age at transplantation was 48 years (range: 35–64) and the median number of treatment lines prior to transplantation was 3 (1–10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1–140). Overall, 40 (71%) patients responded to Ibrutinib ; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two- year OS and PFS probabilities were 72% (95% CI: 52–84) and 50% (95% CI: 32– 66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA